Publications by authors named "Filip Baert"

Claim this Profile
D
Diagnosis of Retrograde Cricopharyngeus Dysfunction Using High Resolution Impedance Manometry and Comparison With Control Subjects.
Karlien Raymenants, Friedel Vulsteke, Tim Vanuytsel, Nathalie Rommel, Filip Baert

Clin Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study.
Geert R D'Haens, Mark Löwenberg, Filip Baert, Peter Bossuyt, Tamás Molnár

Lancet Gastroenterol Hepatol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn's Disease.
Suzanne I Anjie, Geert R D'Haens, Filip Baert, Peter Bossuyt, Frank Hoentjen

Inflamm Bowel Dis· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of ustekinumab in Crohn's disease: Descriptive analysis from an observational post-authorisation safety study using I-CARE cohort data.
Laurent Peyrin-Biroulet, Maciej Nazar, Anna Sheahan, Anja Geldhof, Ahlem Azzabi, Filip Baert

Dig Liver Dis· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ustekinumab in Ulcerative Colitis: A Real-Life Effectiveness Study Across Multiple Belgian Centers (SULTAN).
Tom Holvoet, Marie Truyens, Catherine Reenaers, Filip Baert, Stijn Vanden Branden

J Clin Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rigorous Donor Selection for Fecal Microbiota Transplantation in Active Ulcerative Colitis: Key Lessons From a Randomized Controlled Trial Halted for Futility.
Clara Caenepeel, Sara Deleu, Jorge Francisco Vazquez Castellanos, Kaline Arnauts, Sara Braekeleire, Filip Baert

Clin Gastroenterol Hepatol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Change in fatigue in patients with ulcerative colitis or Crohn's disease initiating biologic therapy.
Edouard Louis, Peter Bossuyt, Arnaud Colard, Antoine Nakad, Didier Baert, Filip Baert

Dig Liver Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A transcriptomic score to classify the inflammation-dysplasia-cancer sequence lesions in inflammatory bowel disease.
Anneline Cremer, Nicolas Rosewick, Maxfield Kelsey, Eric Trépo, Frédérick Libert, Filip Baert

J Crohns Colitis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, Geert R D'Haens, Julian Panés, Filip Baert

J Crohns Colitis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a set of measurable outcome indicators for Flemish patients with inflammatory bowel disease.
Liselotte Fierens, Peter Bossuyt, Filip Baert, Didier Baert, Caroline Weltens

Eur J Gastroenterol Hepatol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic Versus Endoscopy-driven Treatment of Crohn's Postoperative Recurrence: A Retrospective, Multicentric, European Study [PORCSE Study].
Jeroen Geldof, Marie Truyens, Michiel Hanssens, Emily Van Gucht, Tom Holvoet, Filip J Baert

J Crohns Colitis· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analytical and diagnostic performance of Theradiag i-Tracker assays on IDS-iSYS for infliximab and adalimumab therapeutic drug monitoring.
Pauline Herroelen, Hilde Vanpoucke, Filip Baert, An-Sofie Decavele, Inge De Cuyper

Clin Chem Lab Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Data and Measurement Instruments Reported in Observational Studies in Inflammatory Bowel Disease: Results from a Systematic Review.
Charlotte Wong, Joep van Oostrom, Valerie Pittet, Peter Bossuyt, Jurij Hanzel, Filip Baert

J Crohns Colitis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.
Séverine Vermeire, Jurij Hanzel, Mark Löwenberg, Marc Ferrante, Peter Bossuyt, Filip Baert

J Crohns Colitis· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies.
Geert D'Haens, Filip Baert, Silvio Danese, Taku Kobayashi, Edward V Loftus

Eur J Gastroenterol Hepatol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrograde Cricopharyngeus Dysfunction, a New Motility Disorder: Single Center Case Series and Treatment Results.
Stijn Arnaert, Joris Arts, Karlien Raymenants, Filip Baert, Kathelijne Delsupehe

J Neurogastroenterol Motil· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of Biological Therapies and Small Molecules in Ulcerative Proctitis: A Belgian Multicenter Cohort Study.
Pauline Lemmens, Edouard Louis, Wouter Van Moerkercke, Lieven Pouillon, Michael Somers, Filip Baert

Clin Gastroenterol Hepatol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a Core Outcome Set for Real-world Data in Inflammatory Bowel Disease: A European Crohn's and Colitis Organisation [ECCO] Position Paper.
Jurij Hanzel, Peter Bossuyt, Valerie Pittet, Mark Samaan, Monika Tripathi, Filip Baert

J Crohns Colitis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
William J Sandborn, Séverine Vermeire, Laurent Peyrin-Biroulet, Marla C Dubinsky, Julian Panes, Filip Baert

Lancet· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Laurent Peyrin-Biroulet, Jean-François Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Filip Baert

Clin Gastroenterol Hepatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
Edouard Louis, Matthieu Resche-Rigon, David Laharie, Jack Satsangi, Nik Ding, Filip Baert

Lancet Gastroenterol Hepatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study.
Aurelien Amiot, Jean-Francois Rahier, Filip Baert, Stephane Nahon, Ailsa Hart

J Crohns Colitis· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence.
Charlotte Wong, Joep van Oostrom, Peter Bossuyt, Valerie Pittet, Jurij Hanzel, Filip Baert

J Crohns Colitis· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
Geert D'Haens, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel

Lancet· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Marc Ferrante, Remo Panaccione, Filip Baert, Peter Bossuyt, Jean-Frederic Colombel

Lancet· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis